Marketing a drug under heavy regulation

# Marketing a drug under heavy regulation

A Super Bowl ad can promise that a soda makes you happy. A prescription drug ad, in the same commercial break, has to recite a list of side effects that can include death. That contrast is the whole lesson.

The product is regulated, the claims are regulated, the audience is often restricted, and getting it wrong has produced some of the largest corporate settlements on record. Marketing here does not start with a positioningpositioningThe mental space you want your brand to occupy in your target customer's mind relative to alternatives.View full definition → workshop. It starts with a document written by a regulator, and everything the brand says has to fit inside it.

Why pharma marketing is different

Every claim must match the drug's approved label: the official text a regulator signs off on, setting out which condition the drug treats, in which patients, at what dose, and with which warnings. That approved use is called the "indication."

In the United States the regulator is the FDA (Food and Drug Administration). In Europe it is the EMA (European Medicines Agency), working with the national agencies.

Promoting a drug for anything outside the label is "off-label promotion," illegal in most major markets and the reason several manufacturers have paid settlements in the billions. The label is the ceiling. You cannot promise more than the science the regulator accepted.

Novo Nordisk shows how literal that is. Semaglutide is sold as Ozempic, approved for type 2 diabetes, and as Wegovy, approved at a higher dose for weight management. Same molecule, two labels, two brands, two sets of permitted claims. Whatever patients say online about Ozempic and weight loss, the commercial team cannot market it that way. The molecule is not the product. The label is.

The great split: HCP vs DTC

Pharma marketing runs on two separate tracks, aimed at two audiences, under two rulebooks.

Track 1: marketing to healthcare professionals (HCPs)

HCP means healthcare professional: doctors, nurses, pharmacists, anyone who prescribes or dispenses. This is the older and larger channel almost everywhere.

• Sales reps (the "detail" force) visiting clinics with pre-approved materials.
• Congress symposia, where a company such as Sanofi presents trial data on a drug like Dupixent to dermatologists or respiratory specialists.
• Journal advertising and peer-reviewed publication of results.
• Digital: gated portals, webinars and e-details open only to verified professionals.

A rep cannot freestyle. They carry claims that have already cleared review, and they are trained on what they may and may not say.

Track 2: direct-to-consumer (DTC)

DTC means marketing a prescription drug straight to patients. Only two countries broadly allow it: the United States and New Zealand. Almost everywhere else, advertising a prescription medicine to the general public is banned.

Sanofi is headquartered in Paris and advertises Dupixent on American television while running nothing comparable at home for the same product. In the EU, companies may run disease-awareness campaigns (teaching the public about eczema, say) but may not name or promote the prescription product to consumers.

Where DTC is legal, the FDA requires "fair balance": risks presented as prominently as benefits. That is the origin of the rapid-fire side effect narration at the end of every US drug commercial, and it is enforced. In 2008 the FDA warned Bayer that its Yaz television commercials overstated what the contraceptive treated and played down its risks; Bayer had to run corrective advertising to undo the impressionimpressionThe total number of times an ad or piece of content is displayed, regardless of clicks. Each display counts as one impression, even to the same person.View full definition →.

You can read the FDA's plain overview of prescription drug advertising rules here: FDA: Prescription Drug Advertising.

Medical affairs: the science referee

Here is a function that barely exists in other industries: medical affairs.

Medical affairs is the scientific arm sitting between R&D and commercial. Its job is to communicate the evidence accurately, and it is deliberately kept off sales targets, because the people who explain the science should not be paid on prescriptions written.

The field role is the MSL (medical science liaison). MSLs are usually PhDs, PharmDs or MDs who meet leading physicians (KOLs, key opinion leaders) to discuss data. The distinction:

• A sales rep promotes the approved product within the label.
• An MSL discusses science, including answers to unsolicited off-label questions, in a non-promotional way.

If a doctor asks a rep an off-label question, the rep generally cannot answer and must route it to medical affairs. That firewall is a compliance requirement, not an org chart quirk.

Evidence is the raw material

A marketing claim is only as good as the study behind it.

The gold standard is the randomized controlled trial (RCT), where patients are randomly assigned to the drug or a comparator, ideally blinded. Regulators weight this evidence heavily, and marketing teams cannot lift a favourable slide from a weak study onto a brochure.

Comparative claims need comparative trials. Bayer's rivaroxaban (Xarelto) was tested against warfarin rather than against placebo, which is what makes any statement relative to warfarin possible at all. A placebo-controlled programme buys you nothing to say about a rival, however well the drug performed.

Then there is real-world evidence (RWE): data from clinical practice, insurance claims and registries rather than controlled trials. It shows how a drug behaves outside the tidy conditions of a study. The FDA and EMA have both expanded their frameworks for using it, though the bar for a promotional claim stays high.

The practical rule: build the message around what the trials actually proved. If the trial measured a surrogate marker (blood sugar coming down) rather than a hard outcome (fewer heart attacks), the claim has to stop where the data stops.

The compliance guardrails on every message

Beyond the label, a web of rules shapes what pharma marketing can do.

1. Fair balance. Benefits and risks travel together. You cannot show the upside and bury the safety information.

2. Substantiation. Every claim needs evidence on file before it goes out. "Better tolerated" requires data showing that.

3. Approval workflows. Most companies run a medical, legal, regulatory (MLR) review: a doctor or scientist, a lawyer and a regulatory expert sign off before anything ships. This is why pharma campaigns move slowly next to consumer goods.

4. Anti-kickback rules. You cannot pay a doctor to prescribe. In the US, the Sunshine Act requires companies to report payments and gifts to physicians publicly, searchable on the government's Open Payments database. A dinner or a speaking fee that looks like an inducement is a legal risk.

5. Country-by-country variation. There is no single global rulebook. In the EU, self-regulation runs through the EFPIA code; in the UK, the ABPI code, enforced by the PMCPA. The teeth are real: in 2023 the ABPI suspended Novo Nordisk's UK arm from membership for two years over promotional breaches involving weight-management material aimed at healthcare professionals. Same company, same molecule, compliant in one market and sanctioned in another.

A concrete scenario

A team launches a new migraine drug. The trial showed a reduction in monthly migraine days versus placebo, with no head-to-head test against the market leader.

What the team can do: state the reduction versus placebo, cite the trial, present the safety profile with fair balance, and have MSLs discuss the full dataset with neurologists.

What the team cannot do: claim it "works better than" the leading competitor, promote it for cluster headaches if that is not on the label, or imply safety in pregnancy the label does not support.

Same drug, same data. The gap between a compliant campaign and a warning letter is whether each claim maps to the evidence and the label.

How this shapes strategy

Because the message is constrained, the competition moves elsewhere:

• Evidence design: the trials you fund decide the claims you will own three years later.
• Scientific relationships with prescribers, built through legitimate exchange rather than incentives.
• Patient support: adherence tools, injection training, nurse lines and education, permitted in markets where straight promotion is not.
• Coverage: whether a payer reimburses the drug decides if any of this reaches a patient at all, which the next lesson takes up.

Regulation does not remove marketing. It moves the contest from slogans to the evidence, and to the label that evidence buys.

Key takeaways

• The approved label is the ceiling. Every claim must match the regulator-approved indication; off-label promotion is illegal in major markets, as Ozempic and Wegovy show with one molecule split across two labels.
• Two tracks, two audiences. HCP marketing exists everywhere; broad direct-to-consumer advertising of prescription drugs is legal in only the US and New Zealand.
• Medical affairs is a firewall. MSLs discuss science non-promotionally and sit apart from sales.
• Evidence is the raw material. Claims need trial data behind them, with fair balance between benefit and risk, and comparative claims need comparative trials.
• Compliance is local as well as global. MLR review, anti-kickback law and national codes such as ABPI shape every message before it ships.